Stockscreener 앱 받기
13.73
4.19%
-0.60
시간 외 거래:
13.69
-0.04
-0.29%
전일 마감가:
$14.33
열려 있는:
$14.11
하루 거래량:
3.89M
Relative Volume:
0.73
시가총액:
$10.95B
수익:
$220.00K
순이익/손실:
$-1.21B
주가수익비율:
-8.5604
EPS:
-1.6039
순현금흐름:
$-387.48M
1주 성능:
+4.33%
1개월 성능:
+9.40%
6개월 성능:
-17.24%
1년 성능:
-43.78%
1일 변동 폭
$13.43
$14.24
1주일 범위
$12.22
$15.10
52주 변동 폭
$12.07
$29.23
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
13.73 | 9.92B | 220.00K | -1.21B | -387.48M | -1.6039 |
VRTX
Vertex Pharmaceuticals Inc
|
541.69 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
794.19 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,023.21 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.99 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.88 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-08 | 개시 | Stifel | Buy |
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-17 | 개시 | Barclays | Underweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Neutral |
| 2025-07-01 | 개시 | UBS | Buy |
| 2025-06-11 | 개시 | Leerink Partners | Underperform |
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Summit Therapeutics (NASDAQ:SMMT) Trading Up 7.2%Still a Buy? - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Given "Neutral" Rating at HC Wainwright - MarketBeat
SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Summit Therapeutics (NASDAQ:SMMT) Hits New 1-Year LowHere's Why - MarketBeat
Summit Therapeutics (SMMT) Shares Drop 8.5% Amid Valuation Conce - GuruFocus
Summit Therapeutics Inc. (SMMT) Stock Analysis: A 114% Potential Upside Amid Biotech Innovations - DirectorsTalk Interviews
Summit Therapeutics (NASDAQ:SMMT): What Could Drive Its Next Move? - Kalkine Media
Summit Therapeutics (NASDAQ:SMMT) Shares Down 4.7%Here's Why - MarketBeat
Dimensional Fund Advisors LP Sells 288,067 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard? - Yahoo Finance
Summit Therapeutics Inc. (SMMT) stock price, news, quote and history - Yahoo Finance Singapore
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $28.34, Implies 88% Upside - TradingView
Summit Therapeutics (SMMT) Stock Gains on China Label Expansion for Ivonescimab - GuruFocus
Summit lead drug granted China label expansion (SMMT:NASDAQ) - Seeking Alpha
Can Summit Therapeutics (NASDAQ:SMMT) Extend Its Momentum? - Kalkine Media
Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC - marketscreener.com
Summit Therapeutics (NASDAQ:SMMT) Upgraded at Leerink Partners - MarketBeat
Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 - marketscreener.com
Summit Therapeutics (NASDAQ:SMMT) Stock Price Crosses Above 50-Day Moving AverageTime to Sell? - MarketBeat
Why Is SMMT Stock Tumbling Today? - Stocktwits
Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring a 103% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Did Expanding Ivonescimab Into First-Line Bladder Cancer Just Shift Summit Therapeutics' (SMMT) Investment Narrative? - Sahm
Lowey Dannenberg, P.C. is Investigating Summit Therapeutics - GlobeNewswire
Ivonescimab Expands Into First-Line Bladder Cancer – Summit Therapeutics - Oncodaily
Summit Therapeutics (SMMT) Launches Global Phase II/III Trial fo - GuruFocus
Summit TherapeuticsInitiates Global Phase Ii/Iii Harmoni-Gu1 Trial Of Ivonescimab In Bladder Cancer - TradingView
Summit Therapeutics (NASDAQ: SMMT) launches Phase II/III HARMONi-GU1 bladder cancer study - Stock Titan
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer - Business Wire
Jim Cramer Stock Picks: Summit Therapeutics Is A 'Great Spec'Carvana (NYSE:CVNA) - benzinga.com
The Manufacturers Life Insurance Company Has $11.24 Million Stake in Summit Therapeutics PLC $SMMT - MarketBeat
Clear Street Keeps Their Buy Rating on Summit Therapeutics (SMMT) - The Globe and Mail
Summit Therapeutics Inc. (SMMT) Investor Outlook: Exploring A Potential 117.69% Upside - DirectorsTalk Interviews
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of "Hold" from Analysts - MarketBeat
Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches (SMMT) - Seeking Alpha
Summit Therapeutics (SMMT) Is Down 13.2% After Equity Offering And Ivonescimab Updates Has The Bull Case Changed? - Sahm
Summit Therapeutics Reports Q2 2026 Financial Results and Major Clinical Progress for Ivonescimab - Oncodaily
Summit Therapeutics stock hits 52-week low at 12.52 USD By Investing.com - Investing.com Canada
SMMT|Summit Therapeutics Inc|Price:13.105|Chg%:-0.555 - TradingKey
Summit Therapeutics Inc (SMMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm - Morningstar
Summit Therapeutics Inc (SMMT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Summit Therapeutics Inc (SMMT) Cash Flow - TradingKey
Summit Therapeutics officers investigated for p... - Pluang
Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring a 105.67% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Summit Therapeutics Faces Serious Going-Concern Risk as Cash Shortfall Threatens Operations - The Globe and Mail
Piper Sandler Keeps Their Hold Rating on Summit Therapeutics (SMMT) - The Globe and Mail
SMMT|Summit Therapeutics Inc|Price:13.660|Chg%:-1.320 - TradingKey
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Summit Therapeutics (SMMT) and Progyny (PGNY) - The Globe and Mail
Summit Therapeutics (SMMT) Analyst Maintains Neutral Rating Afte - GuruFocus
SMMT Maintained by Guggenheim -- Price Target Lowered to $38.00 - GuruFocus
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Summit Therapeutics Inc 주식 (SMMT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 12 '26 |
Buy |
13.12 |
3,810,000 |
49,987,200 |
573,883,879 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Soni Manmeet Singh | COO and CFO |
Jun 04 '26 |
Buy |
14.45 |
50,000 |
722,250 |
3,123,603 |
| Xia Yu | Director |
Oct 21 '25 |
Buy |
18.74 |
533,617 |
9,999,983 |
32,057,147 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
8.37%
0.23%
자본화:
|
볼륨(24시간):